Results 11 to 20 of about 14,908,548 (354)

Separating clinical antibodies from repertoire antibodies, a path to in silico developability assessment

mAbs, 2022
Approaches for antibody discovery have seen substantial improvement and success in recent years. Yet, advancing antibodies into the clinic remains difficult because therapeutic developability concerns are challenging to predict.
Christopher Negron, Joyce Fang, Michael J. McPherson, W. Blaine Stine, Andrew J. McCluskey   +4 more
doaj   +2 more sources

Predicting Antibody Developability Profiles Through Early Stage Discovery Screening

mAbs, 2020
Monoclonal antibodies play an increasingly important role for the development of new drugs across multiple therapy areas. The term ‘developability’ encompasses the feasibility of molecules to successfully progress from discovery to development via ...
Marc Bailly, Carl Mieczkowski, Veronica Juan, Essam Metwally, Daniela Tomazela, Jeanne Baker, Makiko Uchida, Ester Kofman, Fahimeh Raoufi, Soha Motlagh, Yao Yu, Jihea Park, Smita Raghava, John Welsh, Michael Rauscher, Gopalan Raghunathan, Mark Hsieh, Yi-Ling Chen, Hang Thu Nguyen, Nhung Nguyen, Dan Cipriano, Laurence Fayadat-Dilman   +21 more
doaj   +2 more sources

A comparative study of the developability of full-length antibodies, fragments, and bispecific formats reveals higher stability risks for engineered constructs

mAbs
Engineered antibody formats, such as antibody fragments and bispecifics, have the potential to offer improved therapeutic efficacy compared to traditional full-length monoclonal antibodies (mAbs).
Itzel Condado-Morales, Fabian Dingfelder, Isabel Waibel, Oliver M. Turnbull, Bhargav Patel, Zheng Cao, Jais Rose Bjelke, Susanne Nedergaard Grell, Anja Bennet, Alissa M. Hummer, Matthew I. J. Raybould, Charlotte M. Deane, Thomas Egebjerg, Nikolai Lorenzen, Paolo Arosio   +14 more
doaj   +2 more sources

Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches

mAbs, 2023
With the growing significance of antibodies as a therapeutic class, identifying developability risks early during development is of paramount importance.
Tushar Jain, Todd Boland, Maximiliano Vásquez   +2 more
doaj   +2 more sources

Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows

mAbs
In vitro assessments for the prediction of pharmacokinetic (PK) behavior of biotherapeutics can help identify corresponding liabilities significantly earlier in the discovery timeline.
Tushar Jain, Bianka Prinz, Alexander Marker, Alexander Michel, Katrin Reichel, Valerie Czepczor, Sylvie Klieber, Wei Sun, Sagar Kathuria, Sevim Oezguer Bruederle, Christian Lange, Lena Wahl, Charles Starr, Alessandro Masiero, Lindsay Avery   +14 more
doaj   +2 more sources

Biologics developability data analysis using hierarchical clustering accelerates candidate lead selection, optimization, and preformulation screening [PDF]

mAbs
Identification of an optimal single protein sequence at the discovery stage for preclinical and clinical development is critical to the rapid development and overall success of a biologic drug.
Kevin James Metcalf, Galen Wo, Jan Paulo Zaragoza, Fahimeh Raoufi, Jeanne Baker, Daoyang Chen, Mehabaw Derebe, Jason Hogan, Amy Hsu, Esther Kofman, David Leigh, Mandy Li, Dan Malashock, Cate Mann, Soha Motlagh, Jihea Park, Karthik Sathiyamoorthy, Madhura Shidhore, Yinyan Tang, Kevin Teng, Katharine Williams, Andrew Waight, Sultan Yilmaz, Fan Zhang, Huimin Zhong, Laurence Fayadat-Dilman, Marc Bailly   +26 more
doaj   +2 more sources

Impact of IgG subclass on monoclonal antibody developability

mAbs, 2023
IgG-based monoclonal antibody therapeutics, which are mainly IgG1, IgG2, and IgG4 subclasses or related variants, have dominated the biotherapeutics field for decades.
Paul Cain, Lihua Huang, Yu Tang, Victor Anguiano, Yiqing Feng   +4 more
doaj   +2 more sources

Developability profiling of a panel of Fc engineered SARS-CoV-2 neutralizing antibodies

mAbs, 2023
To combat the COVID-19 pandemic, potential therapies have been developed and moved into clinical trials at an unprecedented pace. Some of the most promising therapies are neutralizing antibodies against SARS-CoV-2.
Andrew Dippel, Austin Gallegos, Vineela Aleti, Arnita Barnes, Xiaoru Chen, Elizabeth Christian, Jared Delmar, Qun Du, Reza Esfandiary, Erika Farmer, Andrew Garcia, Qing Li, Jia Lin, Weiyi Liu, LeeAnn Machiesky, Neil Mody, Arun Parupudi, Meagan Prophet, Keith Rickert, Kim Rosenthal, Song Ren, Harini Shandilya, Reena Varkey, Kevin Wons, Yuling Wu, Yueh-Ming Loo, Mark T. Esser, Nicole L. Kallewaard, Sarav Rajan, Melissa Damschroder, Weichen Xu, Gilad Kaplan   +31 more
doaj   +2 more sources

Biophysical Analysis of Therapeutic Antibodies in the Early Development Pipeline [PDF]

Biologics: Targets & Therapy
Leon F Willis,1 Nikil Kapur,2 Sheena E Radford,1 David J Brockwell1 1School of Molecular and Cellular Biology, Astbury Centre for Structural Molecular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, LS2 9JT, UK; 2School of Mechanical
Willis LF, Kapur N, Radford SE, Brockwell DJ   +3 more
doaj   +2 more sources

Developing drug-like single-domain antibodies (VHH) from in vitro libraries [PDF]

mAbs
Here, we describe a new VHH library for therapeutic discovery which optimizes humanness, stability, affinity, diversity, developability, and facile purification using protein A in the absence of an Fc domain.
M. Frank Erasmus, Andre A. R. Teixeira, Esteban Molina, Luis Antonio Rodriguez Carnero, Jianquan Li, David Knight, Roberto Di Niro, Camila Leal-Lopes, Adeline Fanni, Hallie Troell, Ashley DeAguero, Laura Spector, Sara D’Angelo, Fortunato Ferrara, Andrew R. M. Bradbury   +14 more
doaj   +2 more sources